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ABSTRACT 24 
 25 
The profile of PC945, a novel triazole antifungal, designed for administration via inhalation, has 26 
been assessed in a range of in vitro and in vivo studies. PC945 was characterized as a potent, 27 
tight-binding inhibitor of Aspergillus fumigatus sterol 14α-demethylase (CYP51A and CYP51B) 28 
activity (IC50, 0.23 μM and 0.22 μM, respectively), with characteristic type II azole binding 29 
spectra. Against 96 clinically isolated A. fumigatus strains, the MIC values of PC945 ranged 30 
from 0.032~>8 μg/ml, whilst those of voriconazole ranged from 0.064~4 μg/ml. 31 
Spectrophotometric analysis of the effects of PC945 against itraconazole-susceptible and -32 
resistant A. fumigatus growth, yielded IC50 (OD) values between 0.0012~0.034 μg/ml, whereas 33 
voriconazole (0.019~>1 μg/ml) was less effective than PC945. PC945 was effective against a 34 
broad spectrum of pathogenic fungi (MIC ranged from 0.0078~2 μg/ml) including Aspergillus 35 
terreus, Trichophyton rubrum, Candida albicans, Candida glabrata, Candida krusei, 36 
Cryptococcus gattii, Cryptococcus neoformans and Rhizopus oryzae (1~2 isolates each). In 37 
addition, when A. fumigatus hyphae or human bronchial cells were treated with PC945, and then 38 
washed, PC945 was found to be quickly absorbed into both target and non-target cells and to 39 
produce persistent antifungal effects. In temporarily neutropenic immunocompromised mice 40 
infected with A. fumigatus intranasally, 50% of the animals survived until day 7 when treated 41 
intranasally with PC945 at 0.56 µg/mouse, while posaconazole showed similar effects (44%) at 42 
14 µg/mouse. This profile affirms that topical treatment with PC945 should provide potent 43 
antifungal activity in the lung.   44 
 45 
  46 
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INTRODUCTION 47 
 48 
The current management of the three major forms of aspergillosis: invasive aspergillosis 49 
(IA), chronic pulmonary aspergillosis (CPA) and allergic bronchopulmonary aspergillosis 50 
(ABPA) (1-4), involves prophylactic or therapeutic administration of triazoles and, infrequently, 51 
surgical intervention (5). Existing antifungal medicines are predominantly dosed either orally or 52 
systemically. These frequently exploited routes of delivery are poor for treating airway disease, 53 
since drug concentrations achieved at the site of infection tend to be lower than those in other, 54 
healthy organs. This is especially so for the liver, which is a site of triazole toxicity: up to 15% of 55 
patients treated with voriconazole experience raised transaminase levels (6, 7). Exposure of the 56 
liver also results in significant drug interactions arising from triazole inhibition of hepatic P450 57 
enzymes (8, 9). 58 
It is evident that there is an unmet clinical need for improved antifungal therapies which elicit 59 
fewer drug interactions; show reduced toxicity; achieve higher and more sustained pulmonary 60 
drug concentrations and also demonstrate potent activity against azole-resistant Aspergillus 61 
strains. Thus, there are several advantages of topical treatment over oral/systemic treatment 62 
which alter the risk benefit ratio of treatment favourably.  An optimised compound for topical 63 
delivery should have prolonged lung tissue residence with limited systemic exposure to display a 64 
better adverse effect profile and eradicate invasive aspergillosis due to high concentration 65 
exposure. We have undertaken an extensive lead optimization program in order to identify potent 66 
azole antifungal agents with optimal properties for topical administration to the lung including 67 
tissue retention and physicochemical properties required for formulation. In this report we 68 
disclose the in vitro and in vivo activity of PC945, which is: 4‐[4‐(4‐{[(3R,5R)‐5‐(2,4‐69 
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difluorophenyl)‐5‐(1H‐1,2,4‐triazol‐1‐ylmethyl)oxolan‐3‐yl]methoxy}‐3‐70 
methylphenyl)piperazin‐1‐yl]‐N‐(4‐fluorophenyl)benzamide (Structure in Fig. 1A); a novel, 71 
triazole, antifungal agent designed specifically for inhaled administration (10). 72 
  73 
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MATERIALS AND METHODS 74 
Antifungal agents. For in vitro antifungal assays, stock solutions of test agents were prepared in 75 
DMSO (2000 μg/ml). For in vivo studies test agents were suspended in physiological saline. 76 
PC945 was synthesised by Sygnature Discovery Ltd (Nottingham, UK), and voriconazole 77 
(Tokyo Chemical Industry UK Ltd., Oxford, UK), posaconazole (Apichem Chemical 78 
Technology Co., Ltd., Zhejiang, China), itraconazole (Arkopharma, Carros, France), 79 
amphotericin B (Selleckchem, Munich, Germany) and caspofungin (Selleckchem, Munich, 80 
Germany) were procured from commercial sources. 81 
 82 
A. fumigatus CYP51 binding assay and enzyme inhibitory activity. A. fumigatus CYP51 83 
binding properties were determined as described by Warrilow et al. (11). Test agents were 84 
titrated against 4 μM recombinant A. fumigatus CYP51A or CYP51B proteins and binding 85 
saturation curves were constructed from the change in the absorbance between the spectral peak 86 
and the trough. A rearrangement of the Morrison equation was used to determine the dissociation 87 
constant (Kd) values when ligand binding was tight (12).  88 
A CYP51 reconstitution assay system was used to determine 50% inhibitory (IC50) 89 
concentrations (13). Test agent was added to a mixture of 0.5 μM CYP51, 1 μM A. fumigatus 90 
cytochrome p450 reductase isoenzyme 1 (AfCPR1), 50 μM eburicol, 4% (w/v) 2-hydroxypropyl-91 
β-cyclodextrin, 0.4 mg ml-1 isocitrate dehydrogenase, 25 mM trisodium isocitrate, 50 mM NaCl, 92 
5 mM MgCl2 and 40 mM 3-(N-morpholino) propanesulfonic acid (MOPS)  (pH ~7.2). The 93 
mixtures were then incubated at 37°C for 10 minutes prior to initiation with 4 mM β-NADPHNa4 94 
followed by shaking for 20 minutes at 37°C. Sterol metabolites were recovered by extraction 95 
with ethyl acetate followed by derivatisation with 0.1 ml N,O-96 
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bis(trimethylsilyl)trifluoroacetamide : trimethylchlorosilane (99:1) and 0.3 ml anhydrous 97 
pyridine prior to analysis by gas chromatography mass spectrometry. 98 
 99 
A. fumigatus sterol analysis. A working suspension of A. fumigatus spores was prepared in 100 
filter-sterilised MOPS RPMI-1640 (RPMI-1640 containing 2 mM L-glutamine, 2% glucose, 101 
0.165 M MOPS, buffered to pH 7 with NaOH) at a final concentration of 8 x 106 spores ml-1. To 102 
each 100 mm Petri dish, 10 ml of the working suspension was added and the dishes were 103 
incubated for 4 h at 35°C and 5% CO2. Samples for baseline determinations were collected by 104 
scraping, pelleted by centrifugation at 2000 rpm for 5 minutes and stored at -80°C. Test 105 
compounds or DMSO (50 µL) were added to the remaining dishes, which were subsequently 106 
gently rocked by hand to disperse the compounds. Dishes were incubated for 2 h at 35°C and 5% 107 
CO2. Samples were collected and processed as described above. Posaconazole and PC945 108 
concentrations of 0.0001, 0.001, 0.01, 0.1 and 1 µg ml-1 were tested. These samples were 109 
prepared in the laboratory at Pulmocide Ltd., and sent to the laboratory in the Centre for 110 
Cytochrome P450 Biodiversity, Institute of Life Science, Swansea University Medical School, 111 
for experimentation. 112 
 Non-saponifiable lipids were extracted as previously reported (14) and were derivatised 113 
with 0.1 ml N,O-bis(trimethylsilyl)trifluoroacetamide : trimethylchlorosilane (99:1) and 0.3 ml 114 
anhydrous pyridine (2 h at 80°C) prior to analysis by gas chromatography mass spectrometry 115 
(15). Sterol composition was calculated using peak areas from the gas chromatograms and the 116 
mass fragmentation pattern compared to known standards were used to confirm sterol identity. 117 
The sterol content of A. fumigatus (basal) and treated A. fumigatus (either DMSO, posaconazole 118 
or PC945) were determined.  119 
 120 
 o
n
 M
arch 27, 2017 by University of W
ales Swansea
http://aac.asm
.org/
D
ow
nloaded from
 
AAC (Research Article, T.Colley) 
7 
 
A. fumigatus cell based ergosterol assay. Growth medium (RPMI-1640, 2 mM L-glutamine, 121 
2% glucose, 0.165 M MOPS, 0.5% BSA, pH 7.0) was added across a 96-well plate and test 122 
agents were added in duplicate. A. fumigatus (NCPF2010) conidia were added across the plate at 123 
a final concentration of 1 x 104 ml-1. After incubation for 24 h at 35°C, media was removed from 124 
all wells and replaced with reaction buffer (Amplex red cholesterol assay kit, ThermoFisher, 125 
A12216) and Amplex red solution. Plates were incubated for 30 minutes at 37°C, protected from 126 
light, after which fluorescence was quantified using a spectrophotometer. Media was removed 127 
from all wells and replaced with crystal violet solution (1% v/v), and plates were incubated at 128 
room temperature on a shaker for 30 minutes. Plates were washed three times with PBS, and 129 
sodium dodecyl sulfate solution (0.1% v/v) was added across the plate to lyse the cells. After 130 
incubation at room temperature for 1 h, absorbance was measured at OD590 using a 131 
spectrophotometer. 132 
 133 
Fluorescent imaging of A. fumigatus infected cells. Human alveolar epithelial cells (A549) 134 
were seeded onto collagen-coated coverslips and incubated at 37°C and 5% CO2 for 24 h. Cells 135 
were incubated in the presence of test agents for 2 h, after which the media was replaced and the 136 
coverslips were incubated at 37°C, and 5% CO2 for 24 h. CellTracker red CMTPX dye 137 
(ThermoFisher, C34552) was added to cell media for 30 minutes, wells were washed with PBS, 138 
and GFP-A. fumigatus conidia, [a kind gift from Professor William Hope, University of 139 
Liverpool], were added to wells at a final concentration of 1 x 103 spores ml-1. After 24 h 140 
incubation at 35°C and 5% CO2, coverslips were washed and affixed to slides using 141 
Fluoroshield™ with DAPI (Sigma, F6057). 142 
 143 
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In vitro antifungal activity against A. fumigatus. Assessment of antifungal activity against a 144 
selection of A. fumigatus laboratory/clinical strains (NCPF2010 [National Collection of 145 
Pathogenic Fungi (NCPF), Bristol, UK], AF72 [NCPF, Bristol, UK], AF91 [NCPF, Bristol, UK], 146 
AF293 [NCPF, Bristol, UK], AF294 [NCPF, Bristol, UK], TR34-L98H [Professor Bretagne, St 147 
Louis Hospital, Paris, France]) was performed according to the European Committee on 148 
Antimicrobial Susceptibility Testing (EUCAST) definitive document EDef 9.3 (16), with the 149 
following exceptions: (i) 0.5% bovine serum albumin (BSA) was added to the growth medium to 150 
avoid any loss of lipophilic compounds by adherence to plastic plate surfaces and (ii) 384-well 151 
plates were used rather than 96-well plates. Growth medium (RPMI-1640, 2mM L-glutamine, 152 
2% glucose, 0.165 M MOPS, 0.5% BSA, pH 7.0) was added across the plate, test agents were 153 
added in quadruplicate and the DMSO concentration was identical across the plates. Conidia 154 
were added across the plate at a final concentration of 1 x 105 ml-1. Plates were incubated for 48 155 
h at 35°C after which turbidity was assessed by measuring optical density (OD) at 530 nm using 156 
a spectrophotometer, and the IC50 and IC90 values were calculated from the concentration-157 
response curve generated for each test compound using a four-parameter logistic equation 158 
(Dotmatics, Bishops Stortford, UK). A. fumigatus ATCC204305 was used as the assay control.  159 
Determination of antifungal activity against 50 A. fumigatus clinical isolates from St Louis 160 
Hospital (Paris, France) was performed with 96-well plates using the modified EUCAST method 161 
in the presence of 0.5% BSA as described above. Antifungal susceptibility testing for 46 A. 162 
fumigatus isolates [obtained from the North West England Mycology Reference Centre] was 163 
performed by Evotec (UK) Ltd (Manchester, UK) according to EUCAST guidelines. Assessment 164 
of the antifungal activity of four of the A. fumigatus strains (ATCC1028, ATCC10894, 165 
ATCC13073, and ATCC16424) was performed according to methodology described by the 166 
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Clinical and Laboratory Standards Institute (CLSI) by Eurofins Panlabs Taiwan Ltd. (Taipei, 167 
Taiwan). 168 
 169 
In vitro antifungal activity against other fungal species. For the measurement of activity 170 
against Cryptococcus gattii, the method described in EUCAST definitive document EDef 7.2 171 
was used and assay plates were incubated statically at 37°C in ambient air for 24 h (± 2 h) unless 172 
poor growth necessitated further incubation to 36 or 48 h (17). Antifungal potency against 173 
Aspergillus flavus, Aspergillus niger and Aspergillus terreus, was determined as set out in 174 
EUCAST definitive document EDef 9.2 and assay plates were incubated at 37°C for 48 h (18). 175 
These tests were conducted at Evotec (UK) Ltd (Manchester, UK). Measurement of activity 176 
against other fungi was performed by Eurofins Scientific according to methodology described by 177 
the Clinical and Laboratory Standards Institute (CLSI) (CLSI M38-A (19) or M27-A2 (20), 178 
www.eurofinspanlabs.com).  179 
 180 
In vitro determination of persistence of action on A. fumigatus hyphae. The persistence of 181 
action of test agents was calculated in A. fumigatus hyphae (NCPF2010). Conidia were diluted in 182 
growth media (RPMI-1640, 2 mM L-glutamine, 2 % glucose, 0.165 M MOPS, pH 7.0) and 183 
added across a 384-well plate at a final concentration of 1x103/well. After incubation at 35oC for 184 
exactly 6 h, test and reference articles or neat DMSO (as vehicle) (0.5 µl /well) were added to the 185 
appropriate wells to give a final concentration of 0.5% DMSO. The plates were incubated for 186 
exactly 20 minutes at 35oC and 5% CO2. After the incubation time had elapsed all wells on the 187 
designated washout plate were aspirated and growth media (100 µl/well) was added across the 188 
plate. For the non-washout plate, after compounds were added to hyphae, no media change was 189 
applied.  Resazurin (0.04% diluted in growth media) was added to all wells of both non-washout 190 
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and washout plates (5 µl/well) to give a final concentration of 0.002% resazurin. The plates were 191 
incubated at 35oC and 5% CO2 for 16 h. Subsequently fluorescence in each well was measured at 192 
λex/λem 545/600 nm using a multiscanner (Clariostar: BMG, Buckinghamshire, UK). The 193 
percentage inhibition for each well was calculated and the IC50 value was calculated from the 194 
concentration-response curve generated for each test compound using a four-parameter logistic 195 
equation (Dotmatics, Bishops Stortford, UK). 196 
 197 
In vitro determination of persistence of action on bronchial epithelial cells. The persistence 198 
of action of test agents was evaluated in immortalised, bronchial, epithelial cells (BEAS2B). 199 
Each experiment consisted of one non-washout plate (96-well) and a parallel washout plate into 200 
which BEAS2Bs were seeded at a concentration of 3x104 cells/well in growth media (RPMI-201 
1640, 2 mM L-glutamine, 10% FCS), and incubated for 24 h at 37oC, 5% CO2. Test and 202 
reference articles or neat DMSO (as vehicle) (0.5 µl /well) were added to the appropriate wells of 203 
the washout plate to give a final concentration of 0.5% DMSO. The plate was incubated for 204 
exactly 1 h at 37oC and 5% CO2. After the incubation time had elapsed all wells on the washout 205 
plate were aspirated and growth media (100 µl/well) was added across the plate. After 24 h 206 
incubation at 37°C, test and reference articles or neat DMSO (as vehicle) (0.5 µl /well) were 207 
added to the appropriate wells of the non-washout plate to give a final concentration of 0.5% 208 
DMSO. The plate was incubated for exactly 1 h at 37oC and 5% CO2 after which A. fumigatus 209 
conidia were added across both plates at a final concentration of 1 x 103/well. Fungal growth was 210 
determined after a further 24 h incubation at 35°C, 5% CO2, by measuring galactomannan (GM) 211 
concentrations, using Platelia GM-EIA kits (Bio-Rad Laboratories, 62794). The percentage 212 
inhibition for each well was calculated and the IC50 value was calculated from the concentration-213 
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response curve generated for each test compound using a four-parameter logistic equation 214 
(Dotmatics, Bishops Stortford, UK). 215 
 216 
In vivo antifungal activity against A. fumigatus infection. Specific pathogen-free A/J mice 217 
(male, 5 weeks old) were purchased from Sankyo Labs Service Co. Ltd. (Tokyo, Japan) and 218 
adapted for 1 week in a temperature (24 ± 1ºC) and humidity (55 ± 5%) controlled room, under a 219 
12 h day-night cycle. The mice were reared on a standard diet and tap water ad libitum. A/J mice 220 
were used for A. fumigatus infection and proved to be more efficiently infected as described 221 
previously (21). Animals were then dosed with hydrocortisone (Sigma H4881, 125 mg/kg, 222 
subcutaneously) on days 3, 2 and 1 before infection, and with cyclophosphamide (Sigma C0768; 223 
250 mg/kg, intraperitoneally) two days before infection to induce temporary neutropenia as 224 
previously reported (22). To avoid bacterial infection, drinking water was supplemented with 225 
tetracycline hydrochloride (Sigma T7660; 1 μg/ml) and ciprofloxacin (Fluka 17850; 64 μg/ml). 226 
A. fumigatus (ATCC13073 [strain: NIH 5233], purchased from the American Type Culture 227 
Collection, Manassas, VA, USA) was grown on malt agar (Nissui Pharmaceutical, Tokyo, Japan) 228 
plates for 6–7 days at room temperature (24 ± 1ºC). Conidia were aseptically dislodged from the 229 
agar plates and suspended in sterile distilled water with 0.05% Tween 80 and 0.1% agar. On the 230 
day of infection, conidial counts were assessed by haemocytometer and the inoculum was 231 
adjusted to obtain a concentration of 1.67 × 108/ml in physiological saline. On day 0, 30 μl of the 232 
conidia suspension was administered intranasally. 233 
Test agents, suspended in physiological saline, were administered daily intranasally (35 μl) 234 
on days 1 to 6 and the survival of animals was recorded for 7 days. The volume inserted 235 
intranasally is reported to achieve almost 60% deposition into the lung (23). Deaths and the body 236 
weights of surviving animals were monitored daily. A body weight loss of > 20%, compared 237 
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with an animal’s weight on day 1, or a mouse death, were both defined as “drop-out” events. 238 
Animals that lost > 20% of their initial body weight were sacrificed. It was observed that A. 239 
fumigatus infection induced a “rolling” behaviour, which was monitored and recorded (24). 240 
Bronchoalveolar lavage fluid (BALF) was collected on day 7 post infection or on the day that the 241 
mouse dropped out of the study. The Aspergillus GM concentration in BALF was determined 242 
with Platelia GM-EIA kits (Bio-Rad Laboratories, 62794). The value was provided as a “cut-off 243 
index” (COI) which was calculated by the formula: COI = OD in sample / OD in cut-off control, 244 
provided by the kit. All animal studies were approved by the Ethics Review Committee for 245 
Animal Experimentation of Nihon University. A. fumigatus studies were approved by the 246 
Microbial Safety Management Committee of Nihon University School of Pharmacy (E-H25-247 
001). 248 
 249 
Statistical analysis     Results are expressed as means ± standard error of the mean (SEM). 250 
Survival analysis was performed by Kaplan-Meier plots followed by the log rank (Mantel-Cox) 251 
tests using the PRISM 6® software program (GraphPad Software Inc., San Diego, CA, USA). 252 
For comparison between groups either the ordinary one-way ANOVA with Tukey’s post hoc 253 
comparison, or the Kruskal-Wallis ANOVA with Dunn’s post hoc comparison was performed. 254 
Statistical significance was defined as P<0.05.  255 
   256 
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RESULTS 257 
CYP51 binding properties. PC945 produced a type II difference spectrum when titrated against 258 
purified A. fumigatus CYP51A and CYP51B enzymes and bound with a similar affinity to 259 
CYP51A as posaconazole (Table 1; Fig. 1B). In contrast, in ligand titration experiments with 260 
purified CYP51B, PC945 yielded a sigmoid binding saturation curve whilst posaconazole gave 261 
the expected tight binding saturation curve (Fig. S1). A modified two site allosteric model gave 262 
the best 'off-the-shelf' fit of the sigmoid PC945 saturation curve yielding Kd1 and Kd2 values of 263 
19298 μM and 0.32 μM. This positive cooperative allosterism suggests either the existence of 264 
two non-equivalent ligand binding sites or the existence of two different binding conformations / 265 
orientations for the PC945 molecule within CYP51B that are responsible for the generation of 266 
the type II difference spectrum. Posaconazole bound tightly to purified CYP51B with a Kd value 267 
of 0.012 μM. 268 
 269 
Inhibitory activity against A. fumigatus CYP51 enzyme. The inhibitory activity of PC945 and 270 
posaconazole against A. fumigatus sterol 14α-demethylases were determined using 0.5 μM A. 271 
fumigatus CYP51A and 0.5 μM CYP51B in the membrane fraction prepared from E. coli 272 
expression clones. Both PC945 and posaconazole were strong tight-binding inhibitors of 273 
CYP51A and CYP51B in vitro activity (Table 1; Fig. 1C), suggesting Ki.app values of below 1 274 
nM for both compounds (25). Moreover, PC945 was equally effective as posaconazole, and both 275 
agents appear to share the same mode of action; by directly coordinating as the sixth axial ligand 276 
of the CYP51 heme iron. No allosterism was observed during the inhibition of AfCYP51B 277 
activity by PC945. 278 
 279 
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Cell based A. fumigatus sterol composition and CYP51 assay. Analysis of sterol composition 280 
was performed by GC-MS. Treatment with increasing concentrations of either posaconazole or 281 
PC945 from 0 to 1 µg ml-1 resulted in the dose dependent accumulation of the 14 α-methylated 282 
sterols (lanosterol and eburicol) and the corresponding depletion of the final sterol product: 283 
ergosterol (Table 2, Fig. 1D).  284 
We also investigated enzyme inhibitory activity in a plate-based A. fumigatus cell-based 285 
ergosterol assay. This test system takes advantage of the fact that cholesterol oxidase can utilise 286 
ergosterol as a substrate with a 65% loss of sensitivity. Oxidation of ergosterol was determined 287 
by observing the conversion of the weakly fluorescent resazurin to the highly red fluorescent 288 
resorufin and was normalised using crystal violet staining. Resembling its inhibitor activity in the 289 
cell-free model of CYP51, PC945 strongly inhibited ergosterol production (IC50 = 0.0047 μg/ml; 290 
0.0069 μM) and was 14 and 2.6-fold more potent than voriconazole (IC50 = 0.067 μg/ml; 0.19 291 
μM) and posaconazole (IC50 = 0.012 μg/ml; 0.017 μM), respectively. 292 
 293 
In vitro antifungal activity against azole susceptible and azole resistant strains of A. 294 
fumigatus. The concentrations of test agents required to achieve 50% inhibition (IC50 [OD]) and 295 
90% inhibition (IC90 [OD]) of the growth of a number of A. fumigatus strains (Itraconazole 296 
susceptible-NCPF2010, AF294, AF293; Itraconazole resistant-AF72, AF91, TR34-L98H), were 297 
calculated from growth curves generated using a modified 384-well EUCAST microdilution 298 
method and compared to positive and negative controls. Overall, PC945 was more active than all 299 
reference compounds including voriconazole, posaconazole, and itraconazole, against 300 
itraconazole-susceptible A. fumigatus strains (26, 27) (NCPF2010, AF294, AF293, Table 3). In 301 
addition, PC945 was the most active test agent against known itraconazole-resistant A. fumigatus 302 
strains (AF72, AF91) (28, 29) (Table 3). Against the A. fumigatus strain L98H, containing the 303 
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environmentally acquired TR34/L98H mutation (30), PC945, voriconazole, itraconazole, and 304 
caspofungin all failed to achieve 90% inhibition of fungal growth, whilst posaconazole displayed 305 
an IC90 value of 0.13 μg/ml. However, PC945 achieved an IC50 value of 0.034 μg/ml against this 306 
strain, thereby revealing it to be 2.5-fold more potent than posaconazole (Table 3). BSA 307 
supplementation was confirmed to have no or little effect on the MIC of voriconazole (2 μg/ml 308 
without BSA, 1-2 μg/ml with BSA), posaconazole (0.03 μg/ml without BSA, 0.06 μg/ml with 309 
BSA), itraconazole (0.25 μg/ml without BSA, 0.125 μg/ml with BSA) and amphotericin B (1 310 
μg/ml without BSA, 2 μg/ml with BSA) using A. fumigatus quality control strain ATCC204305, 311 
but it showed marginal effects on the MIC of PC945, a more lipophilic compound (0.25 μg/ml 312 
without BSA, 0.0625 μg/ml with BSA). 313 
 314 
In vitro antifungal activity against clinically isolated A. fumigatus. Test agents were evaluated 315 
in 50 clinical isolates obtained from the Saint Louis Hospital (Paris, France) and 46 clinical 316 
isolates obtained from the NW Mycology Centre in the UK. PC945 was found to be 2.5 fold 317 
more potent than voriconazole but comparable to posaconazole based on the geometric mean 318 
(Table 4). Among the clinical isolates from the NW Mycology Centre, 13 of the 46 strains were 319 
found to be posaconazole resistant, 7 of 13 posaconazole resistant isolates were confirmed as 320 
itraconazole resistant, and two of them were pan-azole resistant including voriconazole, based on 321 
the EUCAST ECOFF. In five of the posaconazole resistant isolates, PC945 did not inhibit 322 
growth completely at concentrations up to 8 μg/ml. During this assay, the quality control strain 323 
A. fumigatus ATCC204305 was used for validation. In this strain posaconazole showed a MIC of 324 
0.25 µg/mL, within the range set by the EUCAST guidelines. 325 
 326 
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In vitro assessment of antifungal activity using CLSI methodology. Visual assessment of the 327 
growth of four itraconazole susceptible A. fumigatus strains demonstrated that PC945 was the 328 
most potent compound tested with an MIC value of 0.031 μg/ml; whilst voriconazole  and 329 
posaconazole  were less effective (Table 5). Thus the superiority of PC945 to voriconazole on A. 330 
fumigatus growth inhibition was confirmed by the CLSI method as well as the EUCAST 331 
microdilution method. 332 
 333 
Antifungal activity against non-A. fumigatus species. The in vitro activities of PC945, 334 
voriconazole, and posaconazole against 22 pathogenic fungi (1~2 isolates each) are displayed in 335 
Table 6. The data for A. terreus shows it to be more susceptible to PC945 than posaconazole. In 336 
addition, PC945 was found to have antifungal activity against A. carbonarius and A. flavus, 337 
albeit less potently than posaconazole or voriconazole. Against C. albicans, (both azole-338 
susceptible and azole-resistant strains), C. glabrata, and C. krusei, PC945 was generally more 339 
active than voriconazole and equally potent to posaconazole. PC945, voriconazole and 340 
posaconazole were comparable in effectiveness against T. rubrum. The remarkable potency of 341 
PC945 against R. oryzae was seen in a greatly improved MIC (2 μg/ml) when compared to 342 
voriconazole and posaconazole (MIC, > 8 μg/ml). The potency of PC945 against C. neoformans 343 
and C. gattii was higher than or similar to voriconazole and posaconazole. In contrast, A. niger, 344 
A. pullulans, P. chrysogenum, P. citrinum, C. argillaceum, C. globosum, G. zeae (Fusarium 345 
graminearum), L. corymbifera, M. circinelloides, and R. pusillus were not susceptible to PC945 346 
treatment within the concentration range tested. 347 
 348 
In vitro determination of persistence of action. Retention of test agents within the hyphae of A. 349 
fumigatus was determined using a resazurin-based microtitre assay. The inhibition of fungal 350 
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growth, arising from continuous contact of the test compounds with A. fumigatus hyphae for 16 351 
h, was measured and compared with that obtained after contact with drug for only 20 minutes, 352 
followed by washout and incubation for the same period. As seen in Table 7 and Fig. 2B, the 353 
antifungal potency of voriconazole and posaconazole diminished markedly, after short contact 354 
and washout, by a factor of > 93-fold and 4.9-fold, respectively. In contrast, PC945 showed no 355 
change in its antifungal activity between wash and non-wash in this experimental paradigm 356 
(Table 7). It was also observed that PC945 (IC50: 0.00010 μg/ml) was 110 and 4.5-fold more 357 
potent, than either voriconazole or posaconazole at inhibiting hyphal A. fumigatus growth.  358 
In the second system, the persistence of action of PC945 was quantified using GM 359 
production in supernatant as an index of fungal growth. BEAS2B cells were infected with A. 360 
fumigatus, and the effects of a 24 h washout period prior to infection were examined. A one hour 361 
contact time with PC945 followed by 24 h washout resulted in an approximate 11-fold loss of 362 
potency against A. fumigatus, compared with the control in which there was no washout. 363 
Although posaconazole showed a similar or slightly greater loss of potency on washout, it was 364 
notable that voriconazole was ineffective after a 24 h washout. These data imply that only a short 365 
contact period of bronchial epithelial cells with PC945 would be required for the agent to exhibit 366 
a long duration of therapeutic action (Table 7, Fig. 2C).   367 
   368 
In vivo antifungal activity. The potential of intranasally administered PC945 as a daily 369 
therapeutic treatment for pulmonary Aspergillus infection was investigated using 370 
immunocompromised, temporarily neutropenic mice. In this model, 81% of control mice (13/16) 371 
were dead or had dropped out by day 6 post infection and only 19% of mice survived (Table 8, 372 
Fig. 2D). However, it was observed that 50, 63 and 63% of mice dosed with PC945 (0.56, 2.8 373 
and 14 µg/mouse: intranasal application of 0.016, 0.08 and 0.4 mg/ml suspension) survived 374 
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(Table 8, Fig. 2D). In contrast, although the highest dose (70 µg/mouse) showed a 75% survival 375 
rate, the effects of posaconazole at 2.8 and 14 µg/mouse were weaker than that of PC945 at 0.56 376 
µg/mouse (Table 8, Fig. 2E). Furthermore, GM in BALF collected on day 7 post infection, or on 377 
the day that an animal dropped out of the study, was significantly reduced by treatment with 378 
PC945 to a superior degree than obtained with posaconazole treatment (Fig. 2F). Intranasal A. 379 
fumigatus infection is known to cause “rolling” behaviour in mice due to CNS effects via 380 
respiratory-systemic infection (24). In this study it was noted that PC945, but not posaconazole, 381 
substantially inhibited the incidence of this rolling behaviour (supplement Fig. 2).  382 
  383 
 o
n
 M
arch 27, 2017 by University of W
ales Swansea
http://aac.asm
.org/
D
ow
nloaded from
 
AAC (Research Article, T.Colley) 
19 
 
DISCUSSION 384 
It has been demonstrated herein that PC945 is a potent antifungal agent, possessing 385 
activity against a broad range of both azole-susceptible and azole-resistant strains of A. 386 
fumigatus. Against itraconazole-susceptible A. fumigatus strains, PC945 showed an increase in 387 
potency between 20 and 180-fold over voriconazole, and comparable or improved potency 388 
versus posaconazole. In an itraconazole-resistant strain of A. fumigatus with a CYP51A M220V 389 
mutation, obtained from a patient undergoing high-dose itraconazole therapy, and an A. 390 
fumigatus strain harbouring the G54E mutation, recently discovered to be environmentally 391 
acquired (26, 31), PC945 was 6 and 2-fold more potent than voriconazole and posaconazole, 392 
respectively. Furthermore, in a strain of A. fumigatus, isolated in France (30) and displaying an 393 
environmentally acquired TR34/L98H mutation, PC945 was more active than voriconazole, 394 
although it did not achieve 90% inhibition of growth. 395 
Against 96 clinically isolated A. fumigatus strains, obtained from St. Louis Hospital, Paris 396 
and the North West Mycology Centre in the UK (Evotec UK Ltd), the MIC range for PC945 was 397 
found to be between 0.032 and 16 μg/ml, with a geometric mean of 0.17 μg/ml and the MIC50 398 
and MIC90 values were 0.125 and 1.0 μg/ml, respectively. The potency of PC945 was superior to 399 
voriconazole and comparable to posaconazole. It is noteworthy that out of 46 clinical isolates of 400 
A. fumigatus from the NW Mycology Centre, 13 strains were posaconazole resistant and two of 401 
them were pan-azole resistant including voriconazole, based on the EUCAST ECOFF. Several 402 
reports have demonstrated that there is an increasing incidence of itraconazole resistant A. 403 
fumigatus in the north-west due to extensive clinical use of itraconazole in this area of the UK 404 
(32, 33). PC945 showed inhibitory activity against 8 of the 13 azole resistant strains, but did not 405 
inhibit the growth of five strains completely when used at concentrations up to 16 μg/ml. 406 
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Although clearly resistant to azoles, the genetic cause(s) underlying resistance in these strains is 407 
unknown. 408 
 In this study we modified the original EUCAST system. Firstly, for our in-house 409 
screening regimen we adapted the EUCAST methodology to a 384-well system, as this is a more 410 
efficient assay which has been shown in other fungal species to generate comparable data to the 411 
96-well format assay (34). The same final concentration of DMSO was applied across the plate 412 
to compare treatment effects with vehicle control more accurately: currently EUCAST suggests 413 
dilution of compounds with EUCAST media, but some lipophilic or insoluble compounds may 414 
precipitate generating misleading data. In fact, PC945 precipitated in EUCAST media at > 415 
4µg/ml, but voriconazole (less lipophilic) did not. Furthermore, data from Pulmocide and from 416 
the St Louis Hospital in Paris were generated by supplementing growth media with 0.5% BSA, 417 
as this avoids the loss of lipophilic compounds bound to plastic surfaces during the assay and is 418 
not inhibitory to A. fumigatus growth (35, 36). Using the quality control A. fumigatus strain 419 
ATCC204305, we confirmed BSA supplementation did not affect the MIC of known antifungal 420 
agents including voriconazole, posaconazole, itraconazole and amphotericin B. Lastly, at 421 
Pulmocide we used turbidity, determined by assessment of OD using a spectrophotometer, as a 422 
measure of fungal growth to enable more accurate quantification of the inhibitory effects of 423 
treatments. All the modifications above helped to quantify the antifungal activity of test agents 424 
more accurately. 425 
Whilst A. fumigatus represents a severe, global, health risk, other fungal species continue 426 
to be equally problematic. Invasive candidiasis affects 46,000 people each year in the US alone 427 
and an estimated 1 million people with HIV/AIDS contract cryptococcal meningitis worldwide 428 
annually (37, 38). These figures underline the pressing need for safer and more effective 429 
antifungals that deliver a broad spectrum of activity. This report discloses that the novel agent 430 
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PC945 has a broad activity profile against a diverse range of fungal species. The growth of C. 431 
albicans, C. glabrata, and C. krusei, was inhibited by PC945 as strongly as with posaconazole 432 
and 1.7-16 fold more actively than with voriconazole. Against C. neoformans PC945 was two-433 
fold more potent than both voriconazole and posaconazole, whilst C. gattii was equally 434 
susceptible to the inhibitory activities of PC945, voriconazole and posaconazole. Mucormycosis 435 
caused by R. oryzae has a mortality rate of 76% for patients with pulmonary infections (39). In 436 
this study PC945 was particularly effective against R. oryzae (MIC, value of 2.0 μg/ml) whilst 437 
voriconazole and posaconazole had no effect within the concentration range tested. 438 
The proposed mechanism of action of PC945 is inhibition of sterol 14α-demethylase 439 
(CYP51A1), the enzyme required to convert eburicol to 14-demethylated eburicol, an essential 440 
step in the ergosterol biosynthesis pathway in fungi. Type II binding spectra, which display an 441 
Amax at 423-430 nm and a broad trough at 386-412 nm arise through a specific interaction in 442 
which the triazole N-4 nitrogen (posaconazole) or the imadazole ring N-3 nitrogen coordinates as 443 
the sixth axial ligand with the heme iron to form a low-spin CYP51-azole complex (40, 41). 444 
PC945 produced type II difference spectra when titrated against purified A. fumigatus CYP51A 445 
and CYP51B enzymes, and bound with a similar affinity to CYP51A as posaconazole, but 446 
yielded a sigmoid binding saturation curve against CYP51B. This latter binding characteristic of 447 
PC945 was not reflected in the compound’s inhibition of CYP51B activity, suggesting a 448 
difference in the enzyme’s conformation in solution and that adopted when incorporated in cell 449 
membranes. Furthermore, the strong inhibition of CYP51A activity observed with both PC945 450 
and posaconazole, indicative of tight-binding inhibitors (IC50 value approximately half that of the 451 
enzyme concentration present) was tighter than predicted by the calculated Kd values from ligand 452 
binding studies using recombinant CYP51A, suggesting the conformation of purified CYP51A in 453 
solution differs to that in cell membranes. In the sterol composition assay, treatment with 454 
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increasing concentrations of either PC945 or posaconazole, from 0 to 1 µg ml-1, resulted in an 455 
accumulation of the 14-methylated sterols, lanosterol and eburicol, and depletion of the final 456 
sterol product, ergosterol; this being consistent with CYP51 inhibition as the key 457 
pharmacological activity of both agents. In addition, the A. fumigatus cell-based ergosterol assay 458 
demonstrated that PC945 was 14 and 2.6-fold more potent at inhibiting ergosterol production 459 
than voriconazole and posaconazole, respectively. Thus, the mechanism of action of PC945, as 460 
for other triazole antifungals, is the inhibition of fungal sterol 14α-demethylase; resulting in the 461 
depletion of ergosterol in the fungal membrane; thereby disrupting membrane structure and 462 
function and inhibiting growth of the pathogenic organism (14).  463 
A highly desirable feature of topical medicines is a long duration of action ensuring that 464 
the desired therapeutic activity is maintained throughout the inter-dose period. In order to 465 
explore this parameter the persistence of action of PC945 in a number of in vitro systems was 466 
studied. In A. fumigatus hyphae the IC50 value measured for PC945 following a 20 minute 467 
contact period and washout for 16 h was almost unchanged relative to that obtained following 468 
continuous contact with the drug for the same period without washout. Furthermore, in the 469 
BEAS2B cell line, washout for 24 h, after a 1 h contact period, resulted in only an approximate 470 
10-fold loss of potency against A. fumigatus compared with control in which there was no 471 
washout period. This property of cellular persistence, in the absence of the pathogen, may be a 472 
particularly valuable property by enhancing the potential use of PC945 in prophylaxis. 473 
The anti-Aspergillus activity of PC945, administered intranasally, was also investigated 474 
in mice using a survival read-out. PC945 was dosed to animals, pre-treated with a single round of 475 
cyclophosphamide and three rounds of hydrocortisone to induce temporary neutropenia; 476 
followed 24 h later by inoculation with A. fumigatus. In this study 81% of vehicle treated, A. 477 
fumigatus infected mice were classed as dead/dropout by day seven. However, once-daily 478 
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treatment with low dose PC945 showed marked beneficial effects on survival. Whilst 44% of 479 
infected mice survived to day 7 when treated with posaconazole at 14 µg/mouse, those treated 480 
with PC945 showed 50% survival at a 25-fold lower dose (0.56 µg/mouse). Despite displaying 481 
similar antifungal activities as determined by the broth microdilution assay, these results indicate 482 
that PC945 significantly outperforms posaconazole in vivo. This superior profile probably arises 483 
from two factors, the first pharmacokinetic and the second pharmacodynamic. As discussed 484 
earlier, PC945 exhibits a longer duration of action than posaconazole and the molecule is 485 
retained within the lung, such that little systemic exposure results, compared with posaconazole, 486 
after intranasal treatment (unpublished data). As a clinical strategy, topical treatment of the lung 487 
is advantageous over oral or intravenous therapy as it delivers high concentrations of an 488 
antifungal agent directly to the site of infection and avoids unfavourable systemic side-effects. 489 
The benefits of inhaled administration for the treatment of invasive pulmonary aspergillosis has 490 
been shown in numerous studies involving amphotericin B, itraconazole and voriconazole (42-491 
44).  492 
Development of resistance to antifungal therapy is an increasing problem in recent years. 493 
It has been shown that a strategy for avoiding the development of resistance is to ensure that the 494 
ratio of treatment peak concentration to MIC is adequate (45). The relationship between 495 
resistance mutation induction and drug exposure has been well-studied in bacteria. In the case of 496 
levofloxacin use against infection with Pseudomonas aeruginosa, exposure at an AUC/MIC ratio 497 
of 157 was calculated to prevent emergence of resistance (46). In the same manner, delivery of 498 
antifungals directly to the lung enables high AUC/MIC ratios to be achieved locally, reducing the 499 
risk of resistance occurring. 500 
PC945 is the first antifungal specifically designed as a once-daily, topical, inhaled 501 
treatment for Aspergillus infection of the lung. Designed to be retained within the target organ 502 
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(such as lung), treatment with PC945 results in very low systemic exposure (data not shown) 503 
thus reducing the potential risk for unwanted clinical effects. In addition, PC945 exhibits high 504 
levels of plasma protein binding, further reducing the likelihood of problems arising from 505 
circulating drug substance. Therefore, PC945 has the pharmacological and pharmaceutical 506 
properties to be a best-in-class, inhaled therapy for the treatment of A. fumigatus infection in 507 
man. 508 
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FIGURE LEGEND 661 
FIGURE 1 Efficacy of PC945 as an inhibitor of A. fumigatus sterol 14α-demethylase 662 
(CYP51). (a) Structure of PC945, (b) Type II azole binding spectra for A. fumigatus CYP51A 663 
and CYP51B, each experiment was performed 4-6 times although only one replicate is shown (c) 664 
Azole IC50 determinations of posaconazole () and PC945 (), mean relative velocity values 665 
are shown with standard deviations, (d) Sterol composition of A. fumigatus treated with PC945, 666 
the relative levels of lanosterol and eburicol. 667 
 668 
FIGURE 2 Antifungal activity of PC945 against A. fumigatus in vitro and in vivo. 669 
(a) A549 treated with PC945 or posaconazole and infected with GFP-A. fumigatus: green = GFP-670 
A. fumigatus; Blue = DAPI-stained nucleus; Red = Celltracker-stained cytoplasm, (b) Persistence 671 
of action of PC945 and voriconazole on A. fumigatus hyphae, (c) Persistence of action of PC945 672 
and voriconazole on human bronchial cell lines (Beas2B) infected with A. fumigatus, (d, e) 673 
Effect of once daily intranasal treatment of PC945 (0.56, 2.8, 14 µg/mouse) and posaconazole 674 
(2.8, 14, 70 µg/mouse) on survival in A. fumigatus infected immunocompromised mice 675 
(N=8~16), (f) Galactomannan in BALF, each horizontal bar was presented as mean ± SEM from 676 
8 mice per group. # Dead before day 7. *** Significant difference from no infection at P<0.001. 677 
††† Significant difference from infection control at P<0.001. 678 
 679 
 680 
 681 
 682 
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TABLE 1 Azole Kd and IC50 determinations versus A. fumigatus CYP51 (AfCYP51) enzymes 684 
 
Test Agent 
AfCYP51A AfCYP51B 
Kd  
(μM)a 
IC50 
(μM)b 
Kd1 
(μM)a 
Kd2 
(μM)a 
IC50   
(μM) b 
PC945 0.50 0.23 19298 0.32 0.22 
Posaconazole 0.96 0.16 0.012 n/a 0.17 
a Kd determinations used 4 μM purified AfCYP51A and 4 μM AfCYP51B proteins. 685 
b IC50 determinations used 0.5 μM AfCYP51A and 0.5 μM AfCYP51B recovered in the 686 
membrane fraction from the E. coli expression clones. 687 
n/a = not applicable 688 
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TABLE 2 % Sterol composition of A. fumigatus treated with either posaconazole or PC945 705 
 
Sterol 
Sterol compositions (posaconazole-treated [μg/ml]) 
DMSO 0.0001 0.001 0.01 0.1 1 
Ergosterol 100 94.5 87.2 74.7 67.8 67.4 
Ergost-5,7-
dienol 
0 3.3 3.9 0 0 0 
Lanosterol 0 0 3.0 7.0 8.8 8.8 
Eburicol 0 2.2 5.9 18.3 23.4 23.8 
 706 
 
Sterol 
Sterol compositions (PC945-treated [μg/ml]) 
DMSO 0.0001 0.001 0.01 0.1 1 
Ergosterol 100 95.9 94.7 86.7 80.6 71.3 
Ergost-5,7-
dienol 
0 4.1 2.5 3.3 0 0 
Lanosterol 0 0 0 3.6 6.2 9.4 
Eburicol 0 0 2.7 6.5 13.2 19.3 
 707 
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TABLE 3 Antifungal effects of PC945 and known antifungal agents in azole susceptible and azole resistant strains of A. fumigatus a 720 
  IC50 and (IC90) Values for Agent Indicated (μg/ml) 
Strain 
Number 
Resistance 
Mechanism PC945 Voriconazole Posaconazole  Itraconazole 
Amphotericin 
B Caspofungin
NCPF2010 none 0.0084 (0.010) 0.16   (0.20) 0.0086 (0.014)  0.057 (0.085) 0.23 (0.48) 0.11   (>1) 
AF294 none 0.0020 (0.0043) 0.082 (0.27) 0.0056 (0.011)  0.041 (0.052) 0.21 (0.79) >1      (>1) 
AF293 none 0.0012 (0.0041) 0.25   (0.74) 0.010   (0.028)  0.032 (0.23) 0.24 (0.85) >1      (>1) 
AF72 G54E 0.0061 (0.029) 0.019 (0.062) 0.032   (0.19)  0.43 (>1) 0.18 (0.64) 0.10   (>1) 
AF91 M220V 0.0081 (0.059) 0.12   (0.38) 0.024   (0.12)  0.26 (>1) 0.42 (>1) 0.072 (>1) 
L98H TR34/L98H 0.034   (>1) >1      (>1) 0.086   (0.13)  0.22 (>1) 0.14 (0.29) 0.082 (>1) 
a IC50 and IC90 values were determined from optical density measurements  721 
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TABLE 4 In vitro activities of PC945, posaconazole and voriconazole against 96 clinically 731 
isolated A. fumigatus strains a  732 
 MIC (μg/ml) 
Test Agent MIC 
[range] 
Geo-
meanb 
Mode MIC50 MIC90 
PC945 0.032->8 0.17* 0.125 0.125 1 
Voriconazole 0.064-4 0.42 0.5 0.5 1 
Posaconazole 0.016-2 0.1 0.032 0.063 0.5 
a All MIC were determined visually; MIC50 and MIC90 values represent the concentrations 733 
required to inhibit 50 and 90% of the strains tested. 734 
b Geo-mean = geometric mean. 735 
* P < 0.05; PC945 versus the results for posaconazole (One way ANOVA with Tukey’s test). 736 
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TABLE 5 Antifungal effect of PC945 and known antifungal agents on 4 itraconazole susceptible 751 
A. fumigatus strains (CLSI methodology) 752 
 MIC (μg/ml)a  MIC50 (μg/ml)b 
Test Agent Median Interquartile  Median Interquartile 
PC945 0.031* 0.020–0.031  0.011** 0.0083–0.024 
Voriconazole 0.5 0.5–0.5  0.14 0.082–0.15 
Posaconazole 0.047 0.031–6.0  0.015 0.0095–0.016 
a MIC determined visually.  753 
b MIC50 determined using optical density measurements. 754 
* P < 0.05, ** P < 0.01; PC945 versus the results for voriconazole (Kruskal-Wallis one-way 755 
ANOVA with Dunn’s test). 756 
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TABLE 6 Antifungal effects of PC945 and posaconazole on other fungal species 771 
Species (Strain/s) Strains tested 
Culture 
method 
MIC (μg/ml) a 
PC945 Voriconazole Posaconazole
      
Aspergillus carbonarius 
(ATCC8740) 1 CLSI 4 0.5 0.063 
Aspergillus flavus  
(ATCC204304) 1 CLSI >8 2 0.13 
Aspergillus flavus  
(AFL8; NRRC3357)  2 EUCAST 6 0.63 0.16 
Aspergillus niger  
(ATCC1015)  1 EUCAST >8 1 0.20 
Aspergillus terreus  
(AT49; AT7130)  2 EUCAST 0.078 1 0.093 
Penicillium chrysogenum 
(ATCC9480)  1 CLSI >8 2 0.13 
Penicillium citrinum 
(ATCC9849)  1 CLSI >8 >8 0.5 
Trichophyton rubrum 
(ATCC10218)  1 CLSI 0.031 0.063 0.031 
      
Aureobasidium pullulans 
(ATCC9348) 1 CLSI >8 >8 1 
Cladosporium argillaceum 
(ATCC38013) 1 CLSI >8 0.5 0.25 
      
Candida albicans b 
(20240.047; ATCC10231) 2 CLSI 0.081 0.14 0.081 
Candida albicans-AR  b 
(20183.073; 20186.025) 2 CLSI 8.25 10 8.13 
Candida glabrata b  
(ATCC36583; R363) 2 CLSI 0.5 8.13 0.5 
Candida krusei  
(ATCC6258) 1 CLSI 0.125 0.25 0.125 
      
Chaetomium globosum 
(ATCC44699) 1 CLSI >8 1 0.25 
Gibberella zeae (Fusarium 
graminearum)  
(ATCC16106) 
1 CLSI >8 >8 >8 
      
Cryptococcus gattii 
(Clinical isolate) 1 EUCAST 0.25 0.125 0.5 
Cryptococcus neoformans 
(ATCC24067) 1 CLSI 0.008 0.016 0.016 
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Lichtheimia corymbifera 
(ATCC7909)  1 CLSI >8 >8 >8 
Mucor circinelloides 
(ATCC8542) 1 CLSI >8 >8 >8 
Rhizomucor pusillus 
(ATCC16458) 1 CLSI >8 >8 >8 
Rhizopus oryzae  
(ATCC11145) 1 CLSI 2 >8 >8 
      
a Due to the limited number of strains tested, the mean of isolate MICs is presented. 772 
b MIC given is MIC50. 773 
AR = azole resistant, fluconazole and voriconazole. 774 
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TABLE 7 Potency and persistence of action of PC945, posaconazole and voriconazole 791 
 Hyphae  BEAS2B 
Test Agent IC50 (μg/ml)   IC50 (μg/ml)  
 Non-
washout Washout 
Fold 
change  
Non-
washout Washout 
Fold 
change 
PC945 0.00010* 0.000086 x0.87  0.0037 0.043 x11.5 
Voriconazole 0.011 >1 x >93  0.054 >1 x >18.6 
Posaconazole 0.00045 0.0022 x4.90  0.0031 0.046 x14.7 
* P < 0.05; PC945 versus the results for voriconazole (Kruskal-Wallis one-way ANOVA with 792 
Dunn’s test). 793 
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TABLE 8 In vivo activities of PC945 and posaconazole 810 
Test Agent Dose 
(μg/mouse) 
Survivor on DAY7
n/N (%) 
Median survival 
day 
Log-rank 
(Mantel-Cox 
Test) 
p-value 
Vehicle - 3/16   (19) 5 - 
PC945 0.56 4/8  (50) 6 0.14 
 2.8 5/8  (63) 6.5 0.022* 
 14 10/16  (63) undefined 0.0095** 
Posaconazole 2.8 1/8  (13) 5 0.69 
 14 7/16  (44) 6 0.050* 
 70 6/8  (75) undefined 0.0028** 
n = number; N = total. 811 
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